Corcept Therapeutics (CORT) EBIAT (2016 - 2025)
Historic EBIAT for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.7 million.
- Corcept Therapeutics' EBIAT fell 5834.2% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.1 million, marking a year-over-year decrease of 2517.88%. This contributed to the annual value of $141.2 million for FY2024, which is 3304.03% up from last year.
- Latest data reveals that Corcept Therapeutics reported EBIAT of $19.7 million as of Q3 2025, which was down 5834.2% from $35.1 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' EBIAT registered a high of $47.2 million during Q3 2024, and its lowest value of $15.9 million during Q1 2023.
- Its 5-year average for EBIAT is $28.2 million, with a median of $27.8 million in 2024.
- As far as peak fluctuations go, Corcept Therapeutics' EBIAT surged by 8887.42% in 2023, and later plummeted by 5834.2% in 2025.
- Quarter analysis of 5 years shows Corcept Therapeutics' EBIAT stood at $32.1 million in 2021, then crashed by 48.21% to $16.6 million in 2022, then soared by 88.87% to $31.4 million in 2023, then dropped by 1.94% to $30.7 million in 2024, then crashed by 36.03% to $19.7 million in 2025.
- Its EBIAT was $19.7 million in Q3 2025, compared to $35.1 million in Q2 2025 and $20.5 million in Q1 2025.